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Work and home productivity of people living with
HIV in Zambia and South Africa
Ranjeeta Thomasa, Rocco Friebela, Kerrie Barkerb, Lawrence Mwengec,
Sarah Kanemac, Nosivuyile Vanqad, Abigail Harpere,
Nomtha Bell-Mandlad, Peter C. Smithf, Sian Floydg, Peter Bockd,
Helen Aylesh, Sarah Fidleri, Richard Hayesg, Katharina Hauckj,
on behalf of the HPTN 071 (PopART) Study Team
Objective: To compare number of days lost to illness or accessing healthcare for HIV-
positive and HIV-negative individuals working in the informal and formal sectors in
South Africa and Zambia.
Design: As part of the HPTN 071 (PopART) study, data on adults aged 18–44 years
were gathered from cross-sectional surveys of random general population samples in 21
communities in Zambia and South Africa. Data on the number of productive days lost in
the last 3 months, laboratory-confirmed HIV status, labour force status, age, ethnicity,
education, and recreational drug use was collected.
Methods: Differences in productive days lost between HIV-negative and HIV-positive
individuals (’excess productive days lost’) were estimated with negative binomial
models, and results disaggregated for HIV-positive individuals after various durations
on antiretroviral treatment (ART).
Results: From samples of 19330 respondents in Zambia and 18004 respondents in South
Africa, HIV-positive individuals lost more productive days to illness than HIV-negative
individuals in both countries. HIV-positive individuals in Zambia lost 0.74 excess productive
days [95% confidence interval (CI) 0.48–1.01; P<0.001] to illness over a 3-month period.
HIV-positive in South Africa lost 0.13 excess days (95% CI 0.04–0.23;P¼0.007). In Zambia,
those on ART for less than 1 year lost most days, and those not on ART lost fewest days. In
South Africa, results disaggregated by treatment duration were not statistically significant.
Conclusion: There is a loss of work and home productivity associated with HIV, but it is
lower than existing estimates for HIV-positive formal sector workers. The findings
support policy makers in building an accurate investment case for HIV interventions.
Copyright  2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
The majority of people living with HIV (PLWH) are in
their most productive phase of life. Worldwide, 78% of
individuals living with HIV are between the ages of 15
and 49 [1], and most of them are either working, studying
or engaged in housework and caring for children or the
elderly. Prior to the expansion of antiretroviral therapy
(ART) in low-income countries, health status and
productivity of HIV-positive individuals declined as
HIV infection progressed to AIDS and premature death.
This had serious consequences for the social and
economic situations of PLWH and their households.
The expanded availability of ART rapidly restored health
and physical functioning [2] and extended life expectancy
[3,4], thereby restoring and maintaining worker produc-
tivity and the well being of households [5,6].
The success of ART in safe-guarding the livelihoods of
PLWH and their households plays an important role in
motivating the global response to the epidemic [7]. The
ambitious 2015 UNAIDS Fast Track Targets for
improved access to treatment are partly motivated by
modelling predictions of large economic gains because of
improved labour productivity [8,9]. These predictions are
based on evidence of how the productivity of workers in
formal employment recovers before and after ART
initiation. It is unclear, however, whether the predictions
apply to the wider HIV-infected population. In low-
income and middle-income countries (LMICs), the
majority of individuals are not formally employed; in sub-
Saharan Africa, informal sector workers make up 88% of
the labour force [10]. They often have precarious
informal employment without contracts, no paid sick
leave, lower wages and longer working hours, and
therefore, face different incentives with respect to
absenteeism than formal sector workers. Informal
workers may simply be unable to afford taking days off
work. Individuals engaged in housework and those
studying make valuable contributions to households,
communities and the economy, but have also been
excluded from most previous analyses.
We conducted this study in two of the most HIV/AIDS-
affected countries globally; South Africa and Zambia, to
compare the productive days lost (PDLs) by PLWH with
those lost byHIV-negative individuals. It is the first analysis
of the association between PDLs and HIV/AIDS in a
random sample of adults. It includes individuals in formal
and informal employment, and those not in the labour
force. Most previous studies that estimated excess PDLs
analysed employees at one or a few companies, including
tea plantations in Kenya [11–14], mining companies in
South Africa and Botswana [5,15] and a public sector
organization in Zambia [16] (see A1 for a literature review,
http://links.lww.com/QAD/B450). Studies were mostly
small in scale, with a median sample size of 2051 (min: 87,
max: 7666), which included a median number of HIV-
positive of 237 (min: 11, max: 1703). Our study provides a
rare insight into the productivity of PLWH at all stages of
engagement with HIV care, including PLWH before
diagnosis. Only three previous studies [15,17,18] analysed
PLWH at all stages of disease, whereas four [5,12–14]
analysed HIV-positive employees before and after initia-
tion of ART, and two [11,16] focused exclusively on
PLWH shortly before death. Our study design enabled
adjustment for confounders that were collected for HIV-
positive and HIV-negative in the sameway. HIV status was
determined from blood samples taken during the survey
and confirmedwith laboratory testing. All previous studies
except three [15,17,18] benchmarked HIV-positive
individuals against employees with unknown HIV status,
therefore, the comparison groups used by previous studies
may have been distorted by an unknown number of HIV-
positive individuals.
Methods
Study population and data
The survey was conducted as the baseline of the on-going
HPTN 071 (PopART) cluster-randomized trial measur-
ing the effect of a combination prevention intervention
on population level HIV-incidence [19]. HPTN 071 was
implemented in 21 communities: 12 in Zambia covering
four provinces and six districts, and nine in South Africa
in the Cape Metro and Cape Winelands districts of the
Western Cape Province (A2, http://links.lww.com/
QAD/B450).
The study population is a cross-sectional random sample
of adults between 18 and 44 years, residing within a
household in the communities enrolled in the HPTN 071
(PopART) trial. Study participants consented to com-
plete a research questionnaire, and to donate a venous
blood sample annually, which was tested for HIV using
a fourth-generation assay (A3, http://links.lww.com/
QAD/B450). The data used in this article was gathered
between November 2013 and March 2015.
From each randomly selected household, one adult was
randomly selected for participation in the survey (A4,
http://links.lww.com/QAD/B450). The survey gath-
ered information on HIV testing, sociodemographics,
health, economic and behavioural variables. PDLs were
measured as responses to the question ‘In the last 3 months,
how many days have you been prevented from doing your usual
work due to your own sickness or seeking healthcare?’ We
followed convention in the labour economics literature
and defined ‘in the labour force’ (ILF) as those self-
reporting being currently employed, self-employed,
unemployed (looking for work or waiting to start new
work) or waiting to continue agricultural work [20]. ‘Not
in the labour force’ (NILF) included homemakers,
students, retirees and others not looking for work. Those
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reporting being permanently sick or disabled were
excluded from the analysis. If respondents self-reported
being HIV-positive, information was gathered on
whether they were in HIV care, and whether and for
how long they had been on ART.
A full ethics review of the trial protocol (DOI https://
doi.org/10.1186/1745-6215-15-57) was done by the
ethics committees of the University of Zambia,
University of Stellenbosch, and the London School of
Hygiene and Tropical Medicine.
Statistical analysis
We used multivariate negative binomial regression
(NegBin) models with a quadratic variance function to
evaluate the effect of HIV status on PDL. The NegBin
model is appropriate as the dependent variable PDL is
over-dispersed [21] with a variance greater than its mean
(A5, http://links.lww.com/QAD/B450). We used
STATA (version 14; STATA Corp., College Station,
Texas, USA) and its nbreg routine for estimation, and
countfit routine for evaluating model fit of the NegBin
compared with a standard Poisson model [22,23].
Results are presented as bothmarginal effects and predicted
values evaluated at the means of all other covariates. A
positive marginal effect represents the additional or ‘excess
PDLs’ that PLWH lose because of illness and/or accessing
healthcare over 3 months when compared with HIV-
negative individuals. The predicted value represents the
total PDLs for specified subgroups of the sample, measured
in numberof days over 3months. Twomodel specifications
per country were estimated. In the first specification
(models 1a and 2a), HIV status was classified as a binary
indicator representing laboratory-confirmedHIV-positive
and HIV-negative individuals. In the second specification
(models 1b and 2b), four categories of HIV-positive status
were defined, with HIV-negative individuals as the base
case: HIV-positive and not onART,HIV-positive onART
less than 1 year, HIV-positive on ART 1–2 years andHIV-
positive on ART 3 or more years. The models included as
adjustment variables: age, sex, education, ethnic group, use
of recreational drugs and labour force participation status.
All models also included dummy variables for each
community to capture unobservable differences across
communities. Models were estimated separately for
Zambia and South Africa.
Results
The full survey sample included responses from 19 750
(83%) of 23 676 randomly selected individuals in Zambia
and 18 941 (88%) of 21 568 randomly selected individuals
in South Africa (Table 1). Laboratory-confirmed HIV
status was available for 19 330 (98%) participants in
Zambia and 18 004 (95%) in South Africa; of whom 4128
(21%) and 4012 (22%) were HIV-positive, respectively. In
both countries, the majority of PLWH reported not being
on ART. Amongst those HIV-positive and on ART, the
largest proportion were on ART for 3 years or more,
followed by on ART for less than 1 year. The mean
number of PDLs reported for the 3-month period before
the interview was 1.3 days (SD: 6.11 days) for participants
from Zambia and 0.31 days (SD: 3.0 days) for participants
from South Africa. Among PLWH in Zambia, 13%
reported having more than three PDLs in the past 3
months, compared with 7% of HIV-negative individuals.
There was no difference between the two groups in South
Africa (2%). In both countries, average PDLs were higher
for HIV-positive (Zambia: 2.17, SD: 8.31; South Africa:
0.48, SD: 4.29) than HIV-negative (Zambia: 1.03, SD:
5.25; South Africa: 0.26, SD: 2.59) individuals. The
majority of respondents were women and had completed
secondary education. Labour force participation was
higher in South Africa than in Zambia.
In Zambia, PLWH lost a total of 1.70 days over 3 months
on average [95% confidence interval (CI) 1.44–1.95,
Table 2]; these were 0.74 ‘excess PDLs,’ that is, 0.74 more
days (95% CI 0.48–1.01; P< 0.001, model 1a, Table 3)
than HIV-negative individuals, who lost a total of 0.95
(95%CI 0.88–1.02) days (Table 2). Compared with HIV-
negative individuals, being on ART for less than 1 year
was associated with the largest number of excess PDLs
(1.24; 95%CI 0.34–2.14; P¼ 0.007, model 1b), followed
by being on ART between 1 and 2 years (1.08; 95% CI
0.06–2.11; P¼ 0.038, model 1b), being on ART for
three or more years (0.79; 95% CI 0.16–1.41; P¼ 0.014,
model 1b) and being HIV-positive but not on ART (0.61;
95% CI 0.30–0.92; P< 0.001, model 1b). In South
Africa, PLWH lost a total of 0.31 days over 3 months on
average (95% CI 0.22–0.40), an excess of 0.13 days (95%
CI 0.04–0.23; P¼ 0.007, model 2a) compared with
HIV-negative individuals who lost 0.18 days in total (95%
CI 0.15–0.20). We found no significant differences when
HIV-status was disaggregated by duration on ART for
individuals in the South African communities.
When examining differences in total predicted values for
both countries, PDLs were much lower in South Africa
than in Zambia for nearly all subgroups (Table 2). Of the
four groups formed based on HIVand labour force status,
HIV-positive ILF had highest PDLs at 1.88 (95% CI
1.57–2.19) and 0.32 (95% CI 0.23–0.41) in Zambia and
South Africa, respectively, followed by HIV-positive
NILF at 1.54 (95% CI 1.28–—1.80) and 0.26 (95% CI
0.14–0.37), HIV-negative ILF at 1.05 (95% CI 0.94–
1.17) and 0.18 (95% CI 0.15–0.21), and HIV-negative
NILF with lowest PDLs at 0.86 (95% CI 0.78–0.95) and
0.15 (95% CI 0.10–0.20). Predicted PDLs increased with
age. Among HIV-positive individuals, 35–44-year olds
who had been on ART for less than 1 year had highest
PDLs at 3.38 days (95% CI 1.94–4.81) in Zambia and
2.24 days (95% CI 0.19–4.28) in South Africa, whereas
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under 25-year olds who were not on ART had lowest
PDLs at 1.24 days (95% CI 0.97–1.51) in Zambia, and
0.16 days (95% CI 0.09–0.23) in South Africa.
There was no substantial sex difference in predicted PDLs
among HIV-positive and HIV-negative individuals in
both countries. HIV-negative and HIV-positive individ-
uals across all categories who had completed secondary
school had lower PDLs than those with primary school
and higher education in Zambia. In South Africa, those
with higher education had fewest PDLs, followed by
those with secondary education and those with primary
education. Predicted PDLs also differed across regions in
Zambia, but there was little variation across regions in
South Africa. Likelihood ratio tests for comparison with
the Poisson model rejected the null of no over-dispersion
(Table 3), confirming that NegBin provided a better fit
(A6, http://links.lww.com/QAD/B450).
Discussion
This is the first study of productive days lost to illness or
accessing healthcare among HIV-positive and HIV-
negative individuals in a random sample of adults in
sub-Saharan Africa. It offers a rare insight into PDLs for
the large majority of the population that is informally
employed, self-employed, unemployed or not part of the
labour force. The study further provides estimates of the
PDLs of PLWH at different stages of engagement with
HIV care, including those not on treatment, and those
who were unaware of their status (44% in Zambia and
53% in South Africa) [2]. We undertook a direct
comparison of PDLs between HIV-positive and HIV-
negative individuals based on laboratory-confirmed HIV
status. HIV-negative individuals provided an important
benchmark that allowed us to analyse the association
between HIVand PDLs, which is a crucial information in
1066 AIDS 2019, Vol 33 No 6
Table 1. Demographic and socioeconomic characteristics of a random sample of adults 18–44 years of age in 21 communities in Zambia and
South Africa.
Zambia South Africa
N¼19 750 N¼18 941
Productive days lost (PDLs) in the last 3 months 1.3 6.11 0.31 3
PDLs, HIV-positive 2.17 8.31 0.48 4.29
PDLs, HIV-negative 1.03 5.25 0.26 2.59
PDLS >3 days, HIV-positive 526/3952 13% 87/3821 2%
PDLS >3 days, HIV-negative 1069/14 496 7% 208/12 862 2%
Age under 25 years 8894/19 730 45% 6355/18 610 34%
Age 25–34 years 7193/19 730 37% 7597/18 610 41%
Age 35– 44 years 3643/19 730 18% 4658/18 610 25%
Sex
Male 5428/19 733 28% 5816/18 612 31%
Female 14 305/19 733 72% 12 796/18 612 69%
Labour force participation
In the labour force 8785/18 623 47% 15 133/18 400 82%
Not in the labour force 9799/18 623 53% 3112/18 400 17%
Unable to work (permanently sick or injured) 39/18 623 0% 155/18 400 1%
Ethnic group
Bemba 5827/19 750 30% Xhosa 12 048/18 941 64%
Tonga 2453/19 750 12% Multiracial 4803/18 941 25%
Lozi 1547/19 750 8% Afrikaans 526/18 941 3%
Chewa 1404/19 750 7% Othera 1564/18 941 8%
Othera 8519/19 750 43%
Education level
School education less than grade 8 (primary school) 5544/19 668 28% 1472/18 466 8%
School education between grades 8 and 12 (secondary school) 12 808/19 668 65% 15 947/18 466 86%
College, university, or other higher education 1316/19 668 7% 1047/18 466 6%
Use recreational drugs 480/19 629 2% 689/18 432 4%
HIV-status
HIV-negative 15 202/19 330 79% 13 992/18 004 78%
HIV-positive 4128/19 330 21% 4012/18 004 22%
HIV-positive not on ARTb,c 2446/4128 59% 2592/4012 65%
HIV-positive on ART <1 yearb 509/4128 12% 351/4012 9%
HIV-positive on ART 1–2 yearsb 347/4128 8% 268/4012 7%
HIV-positive on ART 3 or more yearsb 714/4128 17% 574/4012 14%
Unknown ART statusb,d 112/4128 3% 227/4012 6%
Data are mean (SD), n (%), or n/N (%).
aAll other ethnic groups varied between 0.03 and 6.69%.
bART status at the start of the 3-month recall period of PDLs; numbers based on responses by those self-reporting being HIV-positive.
cIncludes respondents with lab confirmed HIV-positive status who did not self-report being HIV-positive.
dIncludes respondents with missing self-reported ART status.
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Table 3. Multivariable analysis of factors associated with productive days lost.
Zambia South Africa
Model 1a Model 1b Model 2a Model 2b
HIV-negative (base) – – – –
HIV-positive 0.74MMM[0.48–1.01] 0.13MMM[0.04–0.23]
P<0.001 P¼0.007
HIV-positive not on ART 0.61MMM[0.30–0.92] 0.03[0.05 to 0.11]
P<0.001 P¼0.416
HIV-positive on ART
<1 year
1.24MMM[0.34–2.14] 1.41 [0.004 to 2.82]
P¼0.007 P¼0.051
HIV-positive on ART
1–2years
1.08MM[0.06–2.11] 0.18 [0.19 to 0.54]
P¼0.038 P¼0.341
HIV-positive on ART 3 or
more years
0.79MM[0.16–1.41] 0 [0.13 to 0.14]
P¼0.014 P¼0.961
In the labour force (base) – – – –
Not in the labour force 0.05 [0.21 to 0.11] 0.04 [0.20 to 0.12] 0 [0.08 to 0.08] 0.001 [0.07 to 0.07]
P¼0.571 P¼0.592 P¼0.989 P¼0.982
Under 25 years (base) – – – –
25–34 years 0.25MMM [0.08–0.41] 0.24MMM [0.08–0.40] 0.06MM [0.01–0.12] 0.05 [0.01 to 0.10]
P¼0.003 P¼0.004 P¼0.031 P¼0.082
35–44 years 0.73MMM[0.44–1.02] 0.72MMM[0.43–1.02] 0.11MMM [0.03–0.19] 0.11MMM[0.03–0.19]
P<0.001 P<0.001 P¼0.006 P¼0.006
Female (base) – – – –
Male 0.05 [0.22 to 0.12] 0.04 [0.21 to 0.13] 0.08MMM[0.14 to 0.03] 0.10MMM [0.15 to 0.05]
P¼0.593 P¼0.626 P¼0.002 P¼ <0.000
Bemba (base Zambia)/Xhosa
(base South Africa)
– – – –
Tonga (Zambia)/Multiracial
(South Africa)
0.13 [0.16 to 0.41] 0.14 [0.15 to 0.42] 0.01 [0.09 to 0.11] 0.01 [0.08 to 0.10]
P¼0.383 P¼0.353 P¼0.841 P¼0.850
Lozi (Zambia)/Afrikaans
(South Africa)
0.15 [0.20 to 0.49] 0.14 [0.20 to 0.48] 0.87 [0.84 to 2.59] 0.81 [0.77 to 2.40]
P¼0.403 P¼0.418 P¼0.319 P¼0.314
Chewa (Zambia) 0.22 [0.12 to 0.57] 0.23
P¼0.209 [0.12 to 0.57] P¼0.201
Other 0.03 [0.14 to 0.20] 0.03 [0.14 to 0.21] 0.06 [0.14 to 0.02] 0.07MM [0.14 to 0.00]
P¼0.728 P¼0.711 P¼0.164 P¼0.045
School education less than
grade 8 (primary school,
base)
School education between
grades 8 and 12
(secondary school)
0.23MM [0.43 to 0.03] 0.23MM [0.43 to 0.03] 0.13 [0.29 to 0.03] 0.04 [0.16 to 0.08]
P¼0.026 P¼0.025 P¼0.228 P¼0.513
College, university, or other
higher education
0.2 [0.54 to 0.14] 0.19 [0.53 to 0.15] 0.14 [0.33 to 0.04] 0.05 [0.20 to 0.10]
P¼0.260 P¼0.265 P¼0.135 P¼0.505
Does not use recreational
drugs
Uses recreational drugs 0.54 [0.16 to 1.24] 0.53 [0.17 to 1.22] 0.14 [0.09 to 0.36] 0.16 [0.07 to 0.40]
P¼0.131 P¼0.137 P¼0.235 P¼0.169
Community fixed effects Yes Yes Yes Yes
N 17 397 17 324 16 219 16 086
Likelihood ratio test
(Ho: a¼0)
x2 86 000 85 000 26 000 26 000
Prob at least x2 0.0000 0.0000 0.0000 0.0000
Symbols (MMM) and (MM) denote 99% and 95% statistical confidence levels, respectively; presented are marginal effects evaluated at the means of all
other covariates; data are change in mean PDLs (95% CI), unless otherwise stated. For all factor variables, each category is compared with the base
category. ART, antiretroviral therapy; CI, confidence interval.
countries with competing risks that impede productivity,
most notably other diseases. We analysed PDLs, which
were lost to both sickness and accessing healthcare. Travel
and waiting times at facilities have been identified as
important barriers to accessing and remaining in HIV
care [24]. We performed analyses separately for Zambia
and South Africa because of substantial differences in
labour markets, social security and healthcare systems.
In Zambia, 21% of the sample were HIV-positive and had
0.74 more PDLs than HIV-negative individuals over 3
months, whereas in South Africa, the 22% PLWHs had
only 0.13 more PDLs. Our estimates are markedly lower
than those from previous studies [5,11–17]; the median
excess PDLs across eight previous studies was 5.1 days
over 3 months, with high SD of 9.55 and estimates
ranging between zero and over 33 excess PDLs for HIV-
positive workers in their final year of life. Previous studies
analysed PLWH in formal employment who were not
representative of the population of PLWH, which may
explain some of the divergence. Most formal sector
workers enjoy statutory paid sick leave and have,
therefore, lower opportunity costs of work absenteeism.
Most respondents in our sample were informal sector
workers, or unemployed workers with informal jobs and
less able to afford a day of lost pay. This may explain why
our estimates are lower than those of previous studies.
Moreover, our disaggregated results for Zambia indicate
that the two HIV-positive fractions with the lowest excess
PDLs, that is, those not on ARTand those on ART for 3
years or more together, make up 76% of the HIV-positive
population. It seems reasonable that these groups lose
fewer days than those more recently started on ART,
because the former are in the earlier stages of the disease
(and therefore, not yet on ART), and the latter are virally
suppressed because they have been on ART long-term.
Our comparison of community-level variations in excess
PDLs showed significant differences within Zambia, but
less so across communities in South Africa. These
differences may be driven by a range of unobservable
factors that are not captured in the model, including
variations in economic conditions across regions, health
system differences and social norms. The larger variations
observed in Zambia are most likely because the study
communities are spread across the country, reflecting the
heterogeneity across regions, whereas in South Africa, the
communities are all located in the Western Cape
Province, and thus more likely to be similar in
unobservable characteristics.
Five of nine previous studies were conducted before 2010
when ART was less accessible, or they focused on the
(nowadays) small and nonrepresentative subgroup of
PLWH in their final year of life, or with AIDS [11,15–
17], and it is likely that they had higher PDLs than the
population of PLWH today. Longitudinal studies among
infected agricultural and mining workers are consistent
with our findings. They have demonstrated a V-shaped
pattern for labour force participation and productivity
over the course of HIV disease, declining sharply as
symptoms worsen in the months before ART initiation
and rebounding within a few months to levels close to
those experienced prior to becoming symptomatic
[12,13,25–27]. Across all CD4þ cell count ranges except
less than 50ml, PLWH receiving ARTare less absent than
those not receiving treatment [28].
Estimates of PDL are higher for Zambia than for South
Africa. It is possible that PDLs are affected by the time lost
accessing healthcare, rather than inability towork because
of sickness. As guidelines for both countries stipulate
quarterly clinic visits for PLWH, the differences are likely
explained by variations in travel and clinic waiting timings
between the two countries. However, as the proportion
of PLWH not on ART is only slightly higher in South
Africa, it is unlikely that barriers to access can explain all
differences. We could not find comparable empirical
estimates of waiting times for the two countries; an
evidence gap that requires further research. If PDLs were
mainly explained by inefficiencies in accessing care, then
they could possibly be reduced by supply-side interven-
tions. Differentiated models of care policies, such as
community pick-up points and adherence clubs, are
being rolled out in both countries. They aim to shorten
the time required to pick up drugs, and promise to
remove or lower existing access barriers with possibly
positive effects for PDLs [29].
This study has limitations. First, PDLs are based on self-
reports and did not account for reduced productivity on
working days, possibly underestimating productivity
losses. Most previous studies have used employment
records, but these are not available for informal sector
workers and individuals not in the labour force. It is also
difficult to measure reduced productivity while working.
Second, we had no information on individuals’ clinical
disease stage, and so stratified PDLs for PLWH by self-
reported time on ART, which could have been affected
by recall bias. This would not affect our overall estimates,
but potentially those by treatment stage. However, mean
CD4þ cell count at ART initiation has remained at about
152/ml in the past decade in sub-Saharan Africa [30]. Our
results for Zambia suggest that after 2 years on ART, PDLs
recover almost to those of individuals in earlier disease
stages, a finding corroborated by previous studies on
HIV-positive workers [12,13,25–27]. We also had to rely
on self-reports of ART initiation amongst those self-
reporting being HIV-positive, which may have resulted in
some over-classification of individuals into the ‘not being
on ART category.’ Third, we could not control for all
covariates that may affect PDLs, for example, the presence
of other working age individuals in the household,
something not assessed in our sample. Moreover, women
are overrepresented in our sample, which may bias our
findings. However, we control for sex in all models and
the predicted PDLs for men and women are very similar
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in Zambia, and not statistically different in South Africa.
Finally, our data comes from communities in urban and
periurban areas with comparably high HIV prevalence,
and are therefore, not necessarily representative of other
communities in the two countries.
We have calculated the days of work and home
productivity lost to illness of all individuals irrespective
of whether they were in the labour force, overcoming
ethical issues that arise when comparing the benefits of
interventions between individuals who are working and
those who are not, even if they make positive
contributions to society. These estimates could be used
to calculate the opportunity costs of HIV in monetary
terms, for example, by multiplying the estimates with
gross domestic product (GDP) per capita or minimum
wage rates. However, micro estimates of productivity,
such as ours are incorrect estimates of future financial
gains resulting from prevention or treatment interven-
tions; they may underestimate or overestimate the
aggregate productivity benefits from improved health
[31]. Projection of the future macroeconomic impact
requires more complex general equilibrium modelling,
which considers additional factors, such as the degree to
which infections are concentrated in hard-to-replace
skilled workers, levels of unemployment, the impact of
interventions on life expectancy, education, migration
and changes in public and private savings or investments
[7,31].
Our results provide estimates of the burden of the HIV
epidemic resulting from lost work and home productivity
in Zambia and South Africa. These will be a crucial input
for modelling studies that aim to calculate the number of
days lost to sickness that could be averted through
programs of enhanced HIV prevention and treatment,
and to comprehensively assess the economic benefit of
such programs. We generated predictions of PDLs in
various subgroups so that our findings are useful for a
wide range of future studies. UNAIDS policies directed at
achieving the ambitious 90–90–90 targets [32], are partly
motivated by estimates of improved work productivity
generated by simulation studies [8,9]. Our findings help
to assess the validity of the assumptions on which these
studies were based. For example, our results showed that
HIV-negative workers do not have a null absenteeism rate
(previous studies assumed that they do), and that labour
productivity of persons on ART for three or more years is
very similar to asymptomatic HIV-infected adults
(previous studies assumed that it is substantially less) [8,9].
As part of the United Nations’ Sustainable Development
Goals, the world has pledged to end the AIDS epidemic as
a public health threat by 2030. To reach this ambitious
goal, UNAIDS estimates that domestic and international
investments in HIV programs in LMICs need to increase
by about one-third, from an estimated US$ 19.1 billion in
2016 to US$ 26.2 billion until 2020 [33]. This represents a
substantial allocation of resources that might otherwise be
used for alternative worthwhile projects. At the country
level, HIV interventions must compete against public
investments into other interventions in the areas of health,
education, infrastructure, housing, or agriculture. The
benefits of these investments are commonly assessed on
basis of their economic returns. It is difficult for policy
makers to compare the benefits of the large investments
needed to end the epidemic when their returns are only
measured in terms of health outcomes, even if those are
substantial. The findings from this study form an
important contribution towards building a comprehen-
sive and accurate investment case for HIV prevention and
treatment interventions based upon their monetary
benefits.
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